Friday, November 17, 2017 1:34:48 PM
7:12 am ET November 17, 2017 (Dow Jones)
1212 GMT - Sierra Oncology Inc. says phase I trials to date of a potential treatment for advanced cancer have shown it to be safe and it now plans to focus during the next 12 months on efficacy signals. The U.S. drug developer plans to update the market in February on progress with SRA737, which could be used to treat various forms of cancer including prostate, ovarian, lung and bowel. It hopes to discuss next steps by this time next year and has enough cash to take it to mid-2019. "We have potential for a superior drug profile," Chief Executive Nick Glover told a London conference. "2018 will be important as we continue to read out results on our ongoing clinical program. The opportunity is enormous." (philip.waller@wsj.com)
(END) Dow Jones Newswires
November 17, 2017 07:12 ET (12:12 GMT)
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM